logo
ProjectActive

Knight CNS

Sector: Manufacturing (Industrial) • Location: Latin America and the Caribbean Region

Source: International Finance Corporation (IFC)

IFC is considering providing an up to US$40 million loan to Knight Therapeutics Inc. (“Knight” or the “Company”), a pan-American (ex-USA) specialty pharmaceutical company headquartered in Canada with significant operations in Latin America, to partially finance the acquisition of the rights to manufacture, market and sell Exelon® (rivastigmine) in Canada and Latin America (the “Territory”), as wel

Status
Prospective
Sector
Manufacturing (Industrial), Government, Commercial
Location
Brazil
Updated
19 Nov 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about Knight CNS

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

5 Q
The project “Knight CNS” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Latin America and the Caribbean Region. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

active

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

IFC is considering providing an up to US$40 million loan to Knight Therapeutics Inc. (“Knight” or the “Company”), a pan-American (ex-USA) specialty pharmaceutical company headquartered in Canada with significant operations in Latin America, to partially finance the acquisition of the rights to manufacture, market and sell Exelon® (rivastigmine) in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory (the “Exelon Acquisition”). Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.Founded in 2014 in Montreal, Canada, Knight is pan-American (ex-USA) specialty pharmaceutical company that focused on acquiring or in-licensing and commercializing pharmaceutical products in Canada and Latin America.In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America. In August 2020, Knight completed the 100% acquisition of GBT. With the GBT acquisition, Knight has expanded its operations in Latin America through a direct presence in 10 countries.

Original sector

other

Budget

Location

Country

Brazil

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial), Government, Commercial

Article published date

2025-08-08

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project